5-({4-[3-(2-{2-hydroxy-3-[(methylethyl)amino]propoxy}phenoxy)propoxy]phenyl}carbonyl)-4-imidazolin-2-one | 705290-29-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-({4-[3-(2-{2-hydroxy-3-[(methylethyl)amino]propoxy}phenoxy)propoxy]phenyl}carbonyl)-4-imidazolin-2-one
• 英文别名: 4-[4-[3-[2-[2-Hydroxy-3-(propan-2-ylamino)propoxy]phenoxy]propoxy]benzoyl]-5-methyl-1,3-dihydroimidazol-2-one
• CAS: 705290-29-5
• 化学式: C₂₆H₃₃N₃O₆
• 分子量: 483.565
• InChiKey: JIQOQHOXKNRVPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  35
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
  申请人：Hamilton S. Gregory

  公开号：US20070060748A1

  公开（公告）日：2007-03-15

  This invention provides compounds that possess inhibitory activity against β-adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against β-adrenergic receptors and PDE.

  本发明提供了一种具有对β-肾上腺素能受体和磷酸二酯酶PDE，包括磷酸二酯酶3（PDE3）的抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物；使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法；以及制备具有对β-肾上腺素能受体和PDE抑制活性的药物组合物和化合物的方法。
• COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
  申请人：Artesian Therapeutics, Inc.

  公开号：EP1565472A2

  公开（公告）日：2005-08-24
• [EN] COMPOUNDS WITH MIXED PDE-INHIBITORY AND beta-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE MIXTE D'INHIBITION DE LA PDE ET D'ANTAGONISTE OU D'AGONISTE PARTIEL 20040617
  申请人：ARTESIAN THERAPEUTICS INC

  公开号：WO2004050657A2

  公开（公告）日：2004-06-17

  This invention provides compounds that possess inhibitory activity against β-­adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3 ). This invention further provides pharmaceutical compositions comprising such ­compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against ß-adrenergic receptors and PDE.